PROM1 and cholangiocarcinoma: Several recent studies used new and improved (fourth-generation) CARTs that target proteins highly expressed by CCA, such as CD133[112], MUC-1[113], and integrin αVβ6[114]; these have been shown to be extremely efficient both in the expansion of the CART population and in the lysis of different CCA cell lines, in vitro.